Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 86 of 1,261
  1. US 12123036

    Soluble ACE2 variants and uses therefor

    Northwestern University · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  2. US 12121524

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  3. US 12121828

    Systems and methods of isolation of gallium-68

    Telix ARTMS Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  4. US 12123015

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  5. US 12122998

    Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)

    CRISPR THERAPEUTICS AG · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  6. US 12123012

    Methods and compositions for nucleic acid and protein payload delivery

    LIGANDAL, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  7. US 12121569

    Methods and compositions for CNS delivery of iduronate-2-sulfatase

    Takeda Pharmaceutical Company Limited · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  8. US 12123002

    Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

    VOYAGER THERAPEUTICS, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  9. US 12121503

    Antiviral treatments

    BioCryst Pharmaceuticals, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  10. US 12121525

    Methods for treating GI syndrome and graft versus host disease

    The Board of Regents of the University of Texas System · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  11. US 12123001

    Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  12. US 12122773

    Crystalline hydrate of a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  13. US 12122843

    High affinity monoclonal antibodies targeting glypican-1 and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  14. US 12122846

    Chimeric antigen receptor for tumor targeting

    Fate Therapeutics, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  15. US 12122815

    GIP receptor agonist peptide compounds and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  16. US 12121580

    Antibacterial photodynamic therapy using copper-cysteamine nanoparticles

    The Board of Regents of the University of Texas System · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  17. US 12121541

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  18. US 12121526

    Targeting NCCA-ATP channel for organ protection following ischemic episode

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  19. US 12121608

    Biodegradable implant for sustained trans-nasal delivery of therapeutic agents to the brain

    Northwestern University · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  20. US 12121571

    Recombinant L-asparaginase

    Jazz Pharmaceuticals Ireland Limited · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  21. US 12121522

    Methods of treating cancer with an mTOR inhibitor

    Revolution Medicines, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  22. US 12121540

    CBL inhibitors and compositions for use in adoptive cell therapy

    NURIX THERAPEUTICS, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  23. US 12121523

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Supernus Pharmaceuticals, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  24. WO 2024216080

    RÉGIMES IMMUNOSUPPRESSEURS ET PROCÉDÉS ASSOCIÉS

    BIOGEN MA INC [US] · Granted Oct 17, 2024 · Expires Oct 12, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.